Advances in understanding the genetic and electrophysiological basis of skeletal muscle channelopathies have improved DNA-based diagnosis and tailored treatments.
May support genetic testing in channelopathies; leaves open tailored treatment efficacy pending prospective trials.
The human neurological channelopathies are a rapidly expanding group of mainly genetic conditions that are characterized by dysfunction of membrane-bound glycoproteins (ion channels). The skeletal muscle channelopathies were the first to be characterized in this group. In recent years significant progress has been made in our understanding of the molecular genetic and cellular electrophysiological bases of these disorders. DNA-based diagnosis is now a reality for many of the channelopathies. The advances made have implications for both genetic counselling and for tailoring treatment to specific channelopathies.
No takes yet. Share an insight, caveat, or question.
Davies et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: